Uni-Bio Science Group Limited, an investment holding company, engages in the research and development, manufacture, and distribution of biological and chemical pharmaceutical products to treat human diseases in the People’s Republic of China. More Details
Adequate balance sheet and overvalued.
Share Price & News
How has Uni-Bio Science Group's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 690 is not significantly more volatile than the rest of Hong Kong stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: 690's weekly volatility (8%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: 690 underperformed the Hong Kong Biotechs industry which returned 63.8% over the past year.
Return vs Market: 690 underperformed the Hong Kong Market which returned 29.2% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Uni-Bio Science Group's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall StCompanies Like Uni-Bio Science Group (HKG:690) Can Afford To Invest In Growth
3 months ago | Simply Wall StUni-Bio Science Group (HKG:690) Share Prices Have Dropped 26% In The Last Five Years
4 months ago | Simply Wall StWe're Interested To See How Uni-Bio Science Group (HKG:690) Uses Its Cash Hoard To Grow
Is Uni-Bio Science Group undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate 690's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate 690's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: 690 is unprofitable, so we can't compare its PE Ratio to the HK Biotechs industry average.
PE vs Market: 690 is unprofitable, so we can't compare its PE Ratio to the Hong Kong market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 690's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 690 is good value based on its PB Ratio (3.3x) compared to the HK Biotechs industry average (3.4x).
How is Uni-Bio Science Group forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Uni-Bio Science Group has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Uni-Bio Science Group performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 690 is currently unprofitable.
Growing Profit Margin: 690 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: 690 is unprofitable, but has reduced losses over the past 5 years at a rate of 7% per year.
Accelerating Growth: Unable to compare 690's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 690 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (17.5%).
Return on Equity
High ROE: 690 has a negative Return on Equity (-37.65%), as it is currently unprofitable.
How is Uni-Bio Science Group's financial position?
Financial Position Analysis
Short Term Liabilities: 690's short term assets (HK$181.4M) exceed its short term liabilities (HK$60.4M).
Long Term Liabilities: 690's short term assets (HK$181.4M) exceed its long term liabilities (HK$2.9M).
Debt to Equity History and Analysis
Debt Level: 690 is debt free.
Reducing Debt: 690 has no debt compared to 5 years ago when its debt to equity ratio was 1.9%.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Insufficient data to determine if 690 has enough cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if 690 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Uni-Bio Science Group current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 690's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 690's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 690's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 690's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 690's dividend in 3 years as they are not forecast to pay a notable one for the Hong Kong market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Frank Zhao (55 yo)
Mr. Zhi GangZhao, also known as Frank, CPA, MSc, has been the Chief Executive Officer and Executive Director of Uni-Bio Science Group Limited since April 8, 2019. He has been the Chief Financial Officer at...
CEO Compensation Analysis
Compensation vs Market: Frank's total compensation ($USD416.79K) is above average for companies of similar size in the Hong Kong market ($USD230.00K).
Compensation vs Earnings: Frank's compensation has increased whilst the company is unprofitable.
Experienced Board: 690's board of directors are considered experienced (4.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Uni-Bio Science Group Limited's company bio, employee growth, exchange listings and data sources
- Name: Uni-Bio Science Group Limited
- Ticker: 690
- Exchange: SEHK
- Founded: 2001
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: HK$626.319m
- Shares outstanding: 6.39b
- Website: https://www.uni-bioscience.com
Number of Employees
- Uni-Bio Science Group Limited
- No. 20 Science Park East Avenue
- Unit 502
- New Territories
- Hong Kong
Uni-Bio Science Group Limited, an investment holding company, engages in the research and development, manufacture, and distribution of biological and chemical pharmaceutical products to treat human diseas...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/04/11 10:13|
|End of Day Share Price||2021/04/09 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.